SCHEMBL2567672

SCHEMBL2567672

CC(C)(C)c1cccc(NC(=O)C2CCCNC2c2cccc(F)c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.42
KIF11 P52732 2/20 0.40
RAB9A P51151 3/20 0.39
TP53 P04637 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
NPC1 O15118 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
GAA P10253 1/20 0.38
USP2 O75604 1/20 0.38
RIPK1 Q13546 1/20 0.38
UBE2M P61081 1/20 0.37
DCUN1D1 Q96GG9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16280642 1.00 RXFP1 (0.44) RXFP1SMN1; SMN2POLBTDP1ALDH1A1
SCHEMBL12160774 1.00 RXFP1 (0.44) RXFP1SMN1; SMN2POLBTDP1ALDH1A1
SCHEMBL20426001 1.00 RXFP1 (0.44) RXFP1SMN1; SMN2POLBTDP1ALDH1A1
SCHEMBL29726766 1.00 RXFP1 (0.44) RXFP1SMN1; SMN2POLBTDP1ALDH1A1
SCHEMBL2583638 0.90 RXFP1 (0.49) RXFP1SMN1; SMN2TDP1TP53HDAC3
SCHEMBL12160763 0.90 RXFP1 (0.49) RXFP1SMN1; SMN2TDP1TP53HDAC3
SCHEMBL16280645 0.90 RXFP1 (0.49) RXFP1SMN1; SMN2TDP1TP53HDAC3
SCHEMBL12160788 0.78 RXFP1 (0.50) RXFP1SMN1; SMN2POLBTDP1ALDH1A1
SCHEMBL29726747 0.78 RXFP1 (0.50) RXFP1SMN1; SMN2POLBTDP1ALDH1A1
SCHEMBL18801716 0.78 RXFP1 (0.50) RXFP1SMN1; SMN2POLBTDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4015504-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2022-06-22 EP disclosed
EP-3078658-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2019-04-10 EP disclosed
US-9573897-B2 C5AR antagonists CHEMOCENTRYX, INC. (US) 2017-02-21 US disclosed
US-20110275639-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2011-11-10 US disclosed
EP-2381778-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275639-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 RXFP1 911/4885SMN1; SMN2 2376/4885POLB 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.